Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYLDN9)

Drug Name
Cudetaxestat Drug Info
Synonyms
Cudetaxestat; BLD-0409; PAT-409; 6B7TYB2MJX; 1782070-21-6; UNII-6B7TYB2MJX; 3-((2,6-Dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid; Benzoic acid, 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluoro-; CUDETAXESTAT [INN]; CHEMBL4802146; SCHEMBL16739453; BDBM555280; GLXC-26831; EX-A6053; Cudetaxestat (Synonyms: BLD-0409); US11344533, Compound 1-13; MS-28961; HY-145561; CS-0376048; 3-{[2,6-dichloro-7-fluoro-1-(1-propylpyrazol-4-yl)indol-3-yl]sulfanyl}-2-fluorobenzoic acid; Synthesis of 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid
Indication
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Phase 2 [1]
Cross-matching ID
PubChem CID
91809202
TTD Drug ID
DMYLDN9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Extracellular lysophospholipase D (E-NPP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID28447479-Compound-24 DMDOVIZ N. A. N. A. Patented [3]
Tetra-hydro-carboline derivative 2 DMXTL7V N. A. N. A. Patented [3]
PMID28447479-Compound-14 DMA91X2 N. A. N. A. Patented [3]
Pyrimidinone derivative 5 DMLFY57 N. A. N. A. Patented [3]
Heteroaromatic ring derivative 3 DMKJL5T N. A. N. A. Patented [3]
Pyrazolo[3,4-c]pyridine derivative 1 DMQHCDZ N. A. N. A. Patented [3]
Pyrazole derivative 87 DMGZUAY N. A. N. A. Patented [3]
Pyridine and pyrimidine derivative 1 DMGEYJW Fibrosis GA14-GC01 Patented [3]
Imidazopyrimidinone derivative 1 DMWN17V N. A. N. A. Patented [3]
PMID28447479-Compound-21 DM8PET6 N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular lysophospholipase D (E-NPP2) TTSCIM2 ENPP2_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT05373914) RESPIRARE - A Phase 2, Randomized, Double-blinded, Placebo-controlled, Efficacy and Safety Study of Cudetaxestat (BLD-0409) Assessed Across Three Dose Ranges With or Without Standard of Care (Nintedanib or Pirfenidone) in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health.
2 An updated patent review of autotaxin inhibitors (2017-present). Expert Opin Ther Pat. 2021 May;31(5):421-434.
3 Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.